A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin

Vaccine

Volumn 15, Issue 12-13, 1997, Pages 1473-1478

  Berstad, Aud Katrine Herland ^a   Holst, Johan ^a   Møgster, Bente ^a   Haugen, Inger Lise ^a   Haneberg, Bjørn ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Bordetella pertussis; Cholera toxin; Intranasally

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; FEMALE; HEALTH PROMOTION; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; LUNG LAVAGE; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHOLERA TOXIN; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; PERTUSSIS VACCINE;

EID: 0030952626     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00064-9     Document Type: Article

References (36)

1. Christie, C.D.C., Marx, M.L., Marchant, C.D. and Reising, S.F. The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children. New England Journal of Medicine 1994, 331, 16-21.
2. Halperin, S.A., Bortolussi, R., MacLean, D. and Chisholm, N. Persistence of pertussis in an immunized population: Results of the Nova Scotia enhanced pertussis surveillance program. Journal of Pediatrics 1989, 115, 686-693.
3. Mink, C.A.M., Sirota, N.M. and Nugent, S. Outbreak of pertussis in a fully immunized adolescent and adult population. Archives of Pediatric and Adolescent Medicine 1994, 148, 153-157.
4. Fine, P.E.M. and Clarkson, J.A. Reflections on the efficacy of pertussis vaccines. Review of Infectious Diseases 1987, 9, 866-883.
5. Izurieta, H.S., Kenyon, T.A., Strebel, P.M., Baughman, A.L., Shulman, S.T. and Wharton, M. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clinical Infectious Diseases 1996, 22, 503-507.
6. Long, S.S., Welkon, C.J. and Clark, J.L. Widespread silent transmission of pertussis in families: Antibody correlates of infection and symptomatology. Journal of Infectious Diseases 1990, 161, 480-486.
7. Shahin, R.D., Mink, C.A., Wiedermann, B.L. and Meade, B.D. Laboratory correlates of protection and protective immunity to Bordetella pertussis. In Genetically Engineered Vaccines (Eds J.E. Ciardi et al.). Plenum Press, New York, 1992, pp. 287-292
8. Campbell, P.B., Masters, P.L. and Rohwedder, E. Whooping cough diagnosis: a clinical evaluation of complementing culture and immunofluorescence with enzyme-linked immunosorbent assay of pertussis immunoglobulin A in nasopharyngeal secretions. Journal of Medical Microbiology 1988, 27, 247-254.
9. Goodman, Y.E., Wort, A.J. and Jackson, F.L. Enzyme-linked immunosorbent assay for detection of pertussis immunoglobulin A in nasopharyngeal secretions as an indicator of recent infection. Journal of Clinical Microbiology 1981, 13, 286-292.
10. Granström, G., Askelöf, P. and Granström, M. Specific immunoglobulin A to Bordetella pertussis antigens in mucosal secretion for rapid diagnosis of whooping cough. Journal of Clinical Microbiology 1988, 26, 869-874.
11. Thomas, M.G., Ashworth, L.A.E., Miller, E. and Lambert, H.P. Serum IgG, IgA and IgM responses to pertussis toxin, filamentous hemagglutinin and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. Journal of Infectious Diseases 1989, 160, 838-845.
12. Nagel, J. and Poot-Scholtens, E.J. Serum IgA antibody to Bordetella pertussis as an indicator of infection. Journal of Medical Microbiology 1983, 16, 417-426.
13. Fine, P.E. and Clarkson, J.A. The recurrence of whooping cough: Possible implications for assessment of vaccine efficacy. Lancet 1982, 1, 666-669.
14. Roberts, M., Cropley, I., Chatfield, S. and Dougan, G. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Vaccine 1993, 11, 866-872.
15. Cahill, E.S., O'Hagan, D.T., Illum, L., Barnard, A., Mills, K.H.G. and Redhead, K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous hemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 1995, 13, 455-462.
16. Shahin, R., Leef, M., Eldridge, J., Hudson, M. and Gilley, R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infection and Immunity 1995, 63, 1195-1200.
17. Baumann, E., Binder, B.R., Falk, W., Huber, E.G., Kurz, R. and Rosanelli, K. Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine. Developments in Biological Standardization 1985, 61, 511-516.
18. Thomas, G. Respiratory and humoral immune response to aerosol and intramuscular pertussis vaccine. Journal of Hygiene 1975, 74, 233-237.
19. Aaberge, I.S., Groeng, E.-C., Haugen, I.L., Dalseg, R., Løvik, M. and Haneberg, B. Induction of systemic and mucosal antibodies to pneumococcal antigens by mucosal immunizations. Journal of Cellular Biochemistry 1995, 19 A, (Suppl), 242
20. Wu, H.-Y. and Russell, M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infection and Immunity 1993, 61, 314-322.
21. Kanesaki, T., Murphy, B.R., Collins, P. and Ogra, P.L. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. Journal of Virology 1991, 65, 657-663.
22. Hirabayashi, Y., Kurata, H., Funato, H., Nagamine, T., Aizawa, C., Tamura, S., Shimada, K. and Kurata, T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 1990, 8, 243-248.
23. Holst Fredriksen, J., Frøholm, L.O. and Kjennerud, U. The specificity of antisera against Bordetella pertussis examined by bacterial agglutination. Acta Pathologica Microbiologica et Immunologica Scandinavica, Section B: Microbiology and Immunology 1987, 95, 363-369.
24. Dalseg, R., Wedege, E., Haugen, I.L., Holst, J. and Haneberg, B. Group B meningococcal OMV vaccine as a mucosal immunogen. Clinical Immunology and Immunopathology 1995, 76, S93
25. Yetter, R.A., Lehrer, S., Ramphal, R. and Small, P.A. Outcome of influenza infection: Effect of site of initial infection and heterotypic immunity. Infection and Immunity 1980, 29, 654-662.
26. Reuman, P.D., Keely, S.P. and Schiff, G.M. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV. Journal of Medical Virology 1991, 35, 192-197.
27. Langermann, S., Palaszynski, S., Sadziene, A., Kendall Stover, C. and Koenig, S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 1994, 372, 552-555.
28. Roberts, M., Bacon, A., Rappuoli, R., Pizza, M., Cropley, I., Douce, G., Dougan, G., Marinamo, M., McGhee, J. and Chatfield, S. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infection and Immunity 1995, 63, 2100-2108.
29. Walker, R.L. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12, 387-400.
30. Tamura, S., Samegai, Y., Kurata, H., Nagamine, T., Aizawa, C. and Kurata, T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 1988, 6, 409-413.
31. Hordnes, K., Tynning, T., Brown, T.A., Haneberg, B. and Jonsson, R. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 1997, 15, 1244-1251.
32. Wright, P.F. Pertussis in developing countries: Definition of the problem and prospects for control. Review of Infectious Diseases 1991, 13, (Suppl.6), S528-S534.
33. Thomas, M.G., Ashworth, L.A.E., Miller, E. and Lambert, H.P. Nasal immunoglobulin A responses to pertussis toxin, filamentous hemagglutinin and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. In Proceedings of the 6th International Symposium on Pertussis, 1990, US Public Health Service, FDA, pp. 330-334
34. Van Savage, J., Decker, M.D., Edwards, K.M., Sell, S.H. and Karzon, D.T. Natural history of pertussis antibody in the infant and effect on vaccine response. Journal of Infectious Diseases 1990, 161, 487-492.
35. Baraff, L.J., Leake, R.D., Burstyn, D.G., Payne, T. and Cody, C.L. Immunologic response to early and routine DTP immunization in infants. Pediatrics 1984, 73, 37-42.
36. Tomoda, T., Ogura, H. and Kurashige, T. Immune responses to Bordetella pertussis infection and vaccination. Journal of Infectious Diseases 1991, 163, 559-563.